View on Pubmed.gov 22360545 | View on doi.org 10.3109/1040923...
Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.
- Departments of Chemistry and Molecular and Experimental Medicine, The Skaggs Institute for Chemical Biology, La Jolla, CA, USA.
Abstract
Protein misassembly into aggregate structures, including cross-β-sheet amyloid fibrils, is linked to diseases characterized by the degeneration of post-mitotic tissue. While amyloid fibril deposition in the extracellular space certainly disrupts cellular and tissue architecture late in the course of amyloid diseases, strong genetic, pathological and pharmacologic evidence suggests that the process of amyloid fibril formation itself, known as amyloidogenesis, likely causes these maladies. It seems that the formation of oligomeric aggregates during the amyloidogenesis process causes the proteotoxicity and cytotoxicity characteristic of these disorders. Herein, we review what is known about the genetics, biochemistry and pathology of familial amyloidosis of Finnish type (FAF) or gelsolin amyloidosis. Briefly, autosomal dominant D187N or D187Y mutations compromise Ca(2+) binding in domain 2 of gelsolin, allowing domain 2 to sample unfolded conformations. When domain 2 is unfolded, gelsolin is subject to aberrant furin endoproteolysis as it passes through the Golgi on its way to the extracellular space. The resulting C-terminal 68 kDa fragment (C68) is susceptible to extracellular endoproteolytic events, possibly mediated by a matrix metalloprotease, affording 8 and 5 kDa amyloidogenic fragments of gelsolin. These amyloidogenic fragments deposit systemically, causing a variety of symptoms including corneal lattice dystrophy and neurodegeneration. The first murine model of the disease recapitulates the aberrant processing of mutant plasma gelsolin, amyloid deposition, and the degenerative phenotype. We use what we have learned from our biochemical studies, as well as insight from mouse and human pathology to propose therapeutic strategies that may halt the progression of FAF.
References
Nature. 1986 Oct 2-8;323(6087):455-8
J Neuropathol Exp Neurol. 2002 Jun;61(6):565-71
Nature. 1979 Oct 18;281(5732):583-6
Annu Rev Biochem. 2006;75:607-27
Cited by 103 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.
Electronic publication date October 22, 2013
Neil P Grimster [...] Jeffery W Kelly et al.
Molecules that bind selectively to a given protein and then undergo a rapid chemoselective reaction to form a covalent conjugate...
Journal Article Research Support, Non-U.S. Gov't
Hearing problems in patients with hereditary gelsolin amyloidosis.
Electronic publication date November 3, 2021
Tuuli Mustonen [...] Saku T Sinkkonen et al.
BACKGROUND
Gelsolin amyloidosis (AGel amyloidosis) is a hereditary form of systemic amyloidosis featuring ophthalmological, neurological and cutaneous symptoms. Previous studies based...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •